المؤلفون: Smith, Philip, Bradley, Thomas, Gavarró, Lena Morrill, Goranova, Teodora, Ennis, Darren P., Mirza, Hasan B., De Silva, Dilrini, Piskorz, Anna M., Sauer, Carolin M., Al-Khalidi, Sarwah, Funingana, Ionut-Gabriel, Reinius, Marika A. V., Giannone, Gaia, Lewsley, Liz-Anne, Stobo, Jamie, McQueen, John, Bryson, Gareth, Eldridge, Matthew, Glasspool, R. M., Gourley, C., Kennedy, R., Hall, G., Edmondson, R., Clamp, A., Sundar, S., Walter, A., Hall, M., Gabra, H., Fotopoulou, C., Brockbank, E., Montes, A., Lockley, M., Macintyre, Geoff, Markowetz, Florian, Brenton, James D., McNeish, Iain A.

المساهمون: Cancer Research UK

المصدر: Nature Communications ; volume 14, issue 1 ; ISSN 2041-1723

مصطلحات موضوعية: General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, Multidisciplinary

الإتاحة: https://doi.org/10.1038/s41467-023-39867-7Test
https://www.nature.com/articles/s41467-023-39867-7.pdfTest
https://www.nature.com/articles/s41467-023-39867-7Test

المؤلفون: Smith, Philip, Bradley, Thomas, Gavarró, Lena Morrill, Goranova, Teodora, Ennis, Darren P., Mirza, Hasan B., De Silva, Dilrini, Piskorz, Anna M., Sauer, Carolin M., Al-Khalidi, Sarwah, Funingana, Ionut-Gabriel, Reinius, Marika A. V., Giannone, Gaia, Lewsley, Liz-Anne, Stobo, Jamie, McQueen, John, Bryson, Gareth, Eldridge, Matthew, Glasspool, R. M., Gourley, C., Kennedy, R., Hall, G., Edmondson, R., Clamp, A., Sundar, S., Walter, A., Hall, M., Gabra, H., Fotopoulou, C., Brockbank, E., Montes, A., Lockley, M., Macintyre, Geoff, Markowetz, Florian, Brenton, James D., McNeish, Iain A.

المصدر: Nature Communications ; volume 14, issue 1 ; ISSN 2041-1723

مصطلحات موضوعية: General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, Multidisciplinary

الإتاحة: https://doi.org/10.1038/s41467-023-41611-0Test
https://www.nature.com/articles/s41467-023-41611-0.pdfTest
https://www.nature.com/articles/s41467-023-41611-0Test

المؤلفون: Frangou, E., Bertelli, G., Love, S., Mackean, M. J., Glasspool, R. M., Fotopoulou, C., Cook, A., Nicum, S., Lord, R., Ferguson, M., Roux, R. L., Martinez, M., Butcher, C., Hulbert-Williams, N., Howells, L., Blagden, S. P.

المصدر: Frangou , E , Bertelli , G , Love , S , Mackean , M J , Glasspool , R M , Fotopoulou , C , Cook , A , Nicum , S , Lord , R , Ferguson , M , Roux , R L , Martinez , M , Butcher , C , Hulbert-Williams , N , Howells , L & Blagden , S P 2021 , ' OVPSYCH2 : A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer ' , Gynecologic Oncology , vol. 162 , no. 2 , ....

مصطلحات موضوعية: Ovarian cancer, Quality of life, Clinical trial, Fear of relapse, Fear of progression, /dk/atira/pure/subjectarea/asjc/2700/2729, name=Obstetrics and Gynaecology, /dk/atira/pure/subjectarea/asjc/2700/2730, name=Oncology

وصف الملف: application/pdf

العلاقة: https://discovery.dundee.ac.uk/en/publications/3b118bc3-d432-49dc-bfe3-88ec3ad52fa7Test

الإتاحة: https://doi.org/10.1016/j.ygyno.2021.05.024Test
https://discovery.dundee.ac.uk/en/publications/3b118bc3-d432-49dc-bfe3-88ec3ad52fa7Test
https://discovery.dundee.ac.uk/ws/files/70830128/PIIS0090825821004303.pdfTest
http://www.scopus.com/inward/record.url?scp=85107030531&partnerID=8YFLogxKTest

المؤلفون: Banerjee, S., Giannone, G., Clamp, Andrew R, Ennis, D. P., Glasspool, R. M., Herbertson, R., Krell, J., Riisnaes, R., Mirza, H. B., Cheng, Z., McDermott, J., Green, C., Kristeleit, R. S., George, A., Gourley, C., Lewsley, L. A., Rai, D., Banerji, U., Hinsley, S., McNeish, I. A.

المساهمون: Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom

العلاقة: https://dx.doi.org/10.1001/jamaoncol.2022.7966Test; Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, et al. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial. JAMA Oncol. 2023 Mar 16. PubMed PMID: 36928279. Pubmed Central PMCID: PMC10020933 grants from Lady Garden Foundation Charity, and personal fees from AstraZeneca during the conduct of the study; grants from GSK, personal fees from AstraZeneca, GSK, Amgen, Clovis, Eisai, Epsilogen, Immunogen, Mersana, MSD, Novartis, Novocure, OncXerna, Pfizer, Regeneron, Roche, Shattuck Labs, and Takeda outside the submitted work. Dr Giannone reported personal fees from Mylan, AccMed, and Polistudium outside the submitted work. Dr Clamp reported grants from AstraZeneca during the conduct of the study; grants from AstraZeneca and personal fees from AstraZeneca, MSD, Clovis Oncology, GSK, and Immunogen outside the submitted work. Dr Glasspool reported funding to support the trial activity from AstraZeneca and Cancer Research UK during the conduct of the study; personal fees from AstraZeneca (speaker and advisory board fees), personal fees from MSD (advisory board), grants from Clovis Oncology, personal fees from Clovis Oncology (speaker and advisory board fees), personal fees from GSK (speaker and advisory board fees), nonfinancial support from GSK (drug donation scheme), other from GSK (medical conference attendance), other from Novartis (fees to institution for a trial steering committee), grants from Boehringer Ingelheim and Lilly/Ignyta, and personal fees from Immunogen (advisory board) outside the submitted work. Dr Kristeleit reported personal fees from Celcuity during the conduct of the study; grants, personal fees, and nonfinancial support (conference attendance) from MSD; personal fees and nonfinancial support (conference attendance) from Clovis Oncology and GSK; personal fees from Basilea, Eisai, Seattle Genetics, AstraZeneca, and Shattuck Labs; and nonfinancial support from AstraZeneca (conference attendance) outside the submitted work. Dr George reported personal fees from AstraZeneca, GSK, and MSD and other from Roche NZ (research review support) outside the submitted work. Dr Gourley reported grants from AstraZeneca during the conduct of the study; grants paid to institution from AstraZeneca, MSD, GlaxoSmithKline, Clovis, BerGenBio, Novartis, Aprea, NuCana, and Medannexin and personal fees from AstraZeneca, MSD, GlaxoSmithKline, Clovis, Roche, NuCana, Chugai, Takeda, Verastem, Eisai, and COR2ED outside the submitted work; in addition, Dr Gourley had a patent for PCT/US2012/040805 issued. Dr Banerji reported other (advisory board) from Carrick Therapeutics, Pegasy, Boehringer Ingelheim, Idea Pharma (Janssen), and grants from Verastem, Carrick Therapeutics, Verastem, and Chugai outside the submitted work; and AstraZeneca funded the investigator-initiated trial of vistusertib in combination with paclitaxel. Dr McNeish reported grants from AstraZeneca (institutional), personal fees from AstraZeneca, Clovis Oncology, GSK, Roche, ScanCell, and Theolytics outside the submitted work. No other disclosures were reported. Epub 2023/03/18. eng.; http://hdl.handle.net/10541/626167Test; JAMA Oncology

الإتاحة: https://doi.org/10.1001/jamaoncol.2022.7966Test
http://hdl.handle.net/10541/626167Test

المؤلفون: Goranova, T, Ennis, D, Piskorz, A M, Macintyre, G, Lewsley, L A, Stobo, J, Wilson, C, Kay, D, Glasspool, R M, Lockley, M, Brockbank, E, Montes, A, Walther, A, Sundar, S, Edmondson, R, Hall, G D, Clamp, A, Gourley, C, Hall, M, Fotopoulou, C, Gabra, H, Freeman, S, Moore, L, Jimenez-Linan, M, Paul, J, Brenton, J D, McNeish, I A

المصدر: British Journal of Cancer ; volume 120, issue 8, page 868-868 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-019-0433-6Test
http://www.nature.com/articles/s41416-019-0433-6.pdfTest
http://www.nature.com/articles/s41416-019-0433-6Test

المؤلفون: Giannone, G., Ennis, D., Mirza, H. B., Cheng, Z., McDermott, J., Lewsley, L. A., Clamp, Andrew R, Herbertson, R. A., Glasspool, R. M., Krell, J., Hinsley, S., Banerji, U., Riisnaes, R., Banerjee, S., McNeish, I.

المساهمون: Surgery and Cancer, Imperial College London - Hammersmith Campus, London

العلاقة: Giannone G, Ennis D, Mirza HB, Cheng Z, McDermott J, Lewsley LA, et al. Targeting PI3K/AKT/mTOR pathway in platinum-resistant ovarian high-grade serous carcinoma: Translational analysis from the randomized phase II OCTOPUS trial. Annals of Oncology. 2022 Jun;33:S384-S. PubMed PMID: WOS:000814982500005.; http://hdl.handle.net/10541/625476Test; Annals of Oncology

الإتاحة: http://hdl.handle.net/10541/625476Test

المؤلفون: Goranova, T, Ennis, D, Piskorz, A M, Macintyre, G, Lewsley, L A, Stobo, J, Wilson, C, Kay, D, Glasspool, R M, Lockley, M, Brockbank, E, Montes, A, Walther, A, Sundar, S, Edmondson, R, Hall, G D, Clamp, A, Gourley, C, Hall, M, Fotopoulou, C, Gabra, H, Freeman, S, Moore, L, Jimenez-Linan, M, Paul, J, Brenton, J D, McNeish, I A

المصدر: EurOPDX Consortium , Goranova , T , Ennis , D , Piskorz , A M , Macintyre , G , Lewsley , L A , Stobo , J , Wilson , C , Kay , D , Glasspool , R M , Lockley , M , Brockbank , E , Montes , A , Walther , A , Sundar , S , Edmondson , R , Hall , G D , Clamp , A , Gourley , C , Hall , M , Fotopoulou , C , Gabra , H , Freeman , S , Moore , L , ....

مصطلحات موضوعية: Journal Article, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre

الإتاحة: https://doi.org/10.1038/bjc.2017.86Test
https://research.manchester.ac.uk/en/publications/9ef2944a-d205-4490-a5c6-509678bde299Test

المؤلفون: Clamp, Andrew R, James, E. C., McNeish, I. A., Dean, A., Kim, J. W., O'Donnell, D. M., Gallardo-Rincon, D., Blagden, S., Brenton, J., Perren, T. J., Sundar, S., Lord, R., Dark, G., Hall, M., Banerjee, S., Glasspool, R. M., Hanna, C. L., Williams, S., Scatchard, K. M., Nam, H., Essapen, S., Parkinson, C., McAvan, L., Swart, A. M., Popoola, B., Schiavone, F., Badrock, J., Fananapazir, F., Cook, A. D., Parmar, M., Kaplan, R., Ledermann, J. A.

المساهمون: The Christie NHS Foundation Trust and University of Manchester, Manchester

العلاقة: https://dx.doi.org/10.1016/S1470-2045Test(22)00283-2.; Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology. 2022 Jul;23(7):919-30. PubMed PMID: WOS:000833519600034.; http://hdl.handle.net/10541/625597Test; Lancet Oncology

الإتاحة: https://doi.org/10.1016/S1470-2045Test(22)00283-2
http://hdl.handle.net/10541/625597Test

المؤلفون: Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J. W., O'Donnell, D. M., Gallardo-Rincon, D., Blagden, S., Brenton, J., Perren, T. J., Sundar, S., Lord, R., Dark, G., Hall, M., Banerjee, S., Glasspool, R. M., Hanna, C. L., Williams, S., Scatchard, K. M., Nam, H., Essapen, S., Parkinson, C., McAvan, L., Swart, A. M., Popoola, B., Schiavone, F., Badrock, J., Fananapazir, F., Cook, A. D., Parmar, M., Kaplan, R., Ledermann, J. A.

مصطلحات موضوعية: Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin, Carcinoma, Ovarian Epithelial/drug therapy/pathology, Fallopian Tubes/pathology, Female, Humans, Middle Aged, Ovarian Neoplasms/pathology, Paclitaxel

العلاقة: https://linkinghub.elsevier.com/retrieve/pii/S1470-2045Test(22)00283-2; Lancet Oncol. 2022 Jul;23(7):919-930. doi:10.1016/S1470-2045(22)00283-2. Epub 2022 Jun 9.; https://rde.dspace-express.com/handle/11287/622507Test; The Lancet. Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(22)00283-2
https://doi.org/10.1016/S1470-2045Test(22)00283-2
https://rde.dspace-express.com/handle/11287/622507Test

المؤلفون: Morgan, Robert David, McNeish, I. A., Cook, A. D., James, E. C., Lord, R., Dark, G., Glasspool, R. M., Krell, J., Parkinson, C., Poole, C. J., Hall, M., Gallardo-Rincon, D., Lockley, M., Essapen, S., Summers, J., Anand, A., Zachariah, A., Williams, S., Jones, R., Scatchard, K., Walther, A., Kim, J. W., Sundar, S., Jayson, Gordon C, Ledermann, J. A., Clamp, Andrew R

المساهمون: The Christie NHS Foundation Trust and University of Manchester, Manchester, UK

العلاقة: https://dx.doi.org/10.1016/s1470-2045Test(20)30591-x; Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, et al. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 2021;22(2):277-88.; http://hdl.handle.net/10541/623941Test; Lancet Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(20)30591-x
http://hdl.handle.net/10541/623941Test